SCYNEXIS Receives FDA Fast Track and QIDP Designations for SCY-247 Antifungal Therapy
核心洞察
The FDA has granted SCYNEXIS both Qualified Infectious Disease Product (QIDP) and Fast Track designations for SCY-247, a second-generation triterpenoid antifungal therapy targeting drug-resistant fungal infections.
SCY-247 demonstrated potent antifungal activity against challenging pathogens including Candida auris and echinocandin-resistant C. glabrata in preclinical studies, with Phase 1 data showing promising safety and pharmacokinetic properties.
The QIDP designation ensures at least 10 years of market exclusivity following approval, while Fast Track status enables accelerated development pathways including more frequent FDA meetings and rolling review eligibility.
SCYNEXIS, Inc. announced that the U.S. Food and Drug Administration has granted both Qualified Infectious Disease Product (QIDP) and Fast Track designations for SCY-247, the company's second-generation triterpenoid antifungal therapy. The dual designations reflect the drug's potential to address serious unmet medical needs posed by life-threatening resistant fungal infections, particularly as multi-drug resistant pathogens like Candida auris continue to spread globally.
Regulatory Advantages and Market Protection
The QIDP designation provides significant commercial benefits, ensuring at least 10 years of market exclusivity for SCY-247 following FDA approval. This designation requires sponsors to demonstrate that their drug is an antibacterial or antifungal agent intended to treat serious or life-threatening infections, with approved QIDP products receiving a 5-year extension to any exclusivity period.
Fast Track designation offers multiple development advantages, including more frequent FDA meetings to discuss development plans, enhanced written communication regarding clinical trial design and biomarker use, eligibility for Accelerated Approval and Priority Review when criteria are met, and access to rolling review processes that allow submission of completed application sections rather than waiting for the entire submission.
Preclinical and Early Clinical Data
"Last year we presented results from multiple preclinical efficacy models consistently showing the potent antifungal activity of SCY-247 against a broad array of fungal pathogens, including some of the most difficult to treat such as Candida auris and echinocandin-resistant C. glabrata, as well as data supporting extensive tissue distribution," said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS.
The company's Phase 1 single ascending dose/multiple ascending dose (SAD/MAD) studies demonstrated SCY-247's promising safety profile and favorable pharmacokinetic properties. Notably, the data showed that SCY-247 could achieve target exposures for invasive fungal disease at doses lower than the company's first-generation fungerp compounds.
Development Timeline and Clinical Plans
SCYNEXIS expects to initiate a Phase 1 study of SCY-247's intravenous formulation in 2026, alongside a Phase 2 study evaluating the oral formulation in invasive candidiasis. The company also aims to release proof-of-concept data for the oral formulation of SCY-247 in invasive candidiasis during 2026.
Given SCY-247's differentiated attributes and potential role in countering health security threats posed by antifungal resistance development, SCYNEXIS continues exploring non-dilutive funding opportunities to support the program's advancement.
Addressing Growing Public Health Threats
Scientific and media publications continue highlighting the urgent need for novel antifungal solutions to combat emerging multi-drug resistant fungal pathogens. In December 2025, a collaborative multi-institution scientific publication reported that Candida auris is spreading globally while gaining virulence. Recent media coverage has emphasized the growing public health threat in the United States from rapidly spreading "superbug" strains of Candida auris, particularly noting the vulnerability of immunocompromised individuals to these infections that do not respond to currently approved antifungal therapies.
SCY-247's broad spectrum of activity positions it to address this growing public health threat through its demonstrated activity against most drug-resistant fungi, including multi-drug-resistant Candida auris and azole-resistant Aspergillus species.
Company Background
SCYNEXIS is developing its proprietary antifungal platform called "fungerps," with ibrexafungerp representing the first approved member of this novel class. The FDA has approved BREXAFEMME (ibrexafungerp tablets) for treating vulvovaginal candidiasis and reducing recurrent vulvovaginal candidiasis incidence. Additional antifungal assets from this class, including SCY-247, are currently in various stages of clinical, preclinical, and discovery development.